TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer

Norikatsu Miyoshi MD, Hideshi Ishii MD, Koshi Mimori MD, Fumiaki Tanaka MD, Toshiki Hitora MD, Mitsuyoshi Tei MD, Mitsugu Sekimoto MD, Yuichiro Doki MD, PhD, Masaki Mori MD, PhD, FACS
Colorectal Cancer
Volume 17, Issue 4 / April , 2009

View full article HTML | View full article PDF | Download Citation

Abstract

Background

Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway.

Methods

We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase–polymerase chain reaction (P = .015).

Results

Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth.

Conclusions

The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.

Go to Issue Contents